F114 Rheumatology for the Dermatologist: Evaluating the Rheumatology Patient in the Dermatology Clinic
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
We will review updates in cutaneous lupus treatment and consider alignment of treatment for both skin and systemic lupus erythematosus. We will review immunosuppression in CTD and relevant monitoring / vaccination as appropriate. We will review dermatomyositis clinical findings (skin and systemic) as they relate to autoantibody profiles. We will review appropriate rheumatology review of systems and approach to inflammatory arthritis for the dermatologist. Other topics will include brief review of systemic sclerosis screening and monitoring.
LEARNING OBJECTIVES
Discuss updates in cutaneous lupus treatment including systemic lupus considerations for the dermatologist; describe dermatomyositis as defined by autoantibody profiles and outline the workup for the systemic sclerosis patient.
Appropriately order and interpret autoimmune serologic testing.
Develop a helpful review of systems to approach systemic rheumatologic disease.
SCHEDULE
8:00 PM
Dermatomyositis: Update and Systemic Considerations
Scott Elman, MD, FAAD
8:20 PM
Cutaneous Lupus: Treatment Update and Systemic Lupus Considerations
Joseph Merola, MD, MSc, FAAD
8:50 PM
Systemic Sclerosis: Considerations for the Dermatologist
Rebecca Gaffney, MD
9:10 PM
Serologies in CTD
Jeffrey Smith, PhD, MD, FAAD
9:25 PM
Therapeutic Monitoring and Safety
Jeffrey Smith, PhD, MD, FAAD
9:35 PM
Cases and Q&A
SPEAKERS
Scott Elman, MD, FAAD
Rebecca Gaffney, MD
Joseph Merola, MD, MSc, FAAD
Jeffrey Smith, PhD, MD, FAAD
SPEAKER DISCLOSURES
Scott Elman, MD, FAAD
Biogen – Consultant(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Rebecca Gaffney, MD
No financial relationships exist with ineligible companies.
Joseph Merola, MD, MSc, FAAD
AbbVie – Consultant(Honoraria); Amgen – Advisory Board(Honoraria); AstraZeneca – Consultant (1099 relationship)(Fees); Biogen – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant (1099 relationship)(Fees); Bristol-Myers Squibb – Consultant (1099 relationship)(Fees); Eli Lilly and Company – Consultant(Honoraria); Janssen Pharmaceuticals, Inc – Consultant(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Pfizer Inc. – Investigator(Fees); Sanofi/Regeneron – Consultant(Honoraria); UCB – Consultant(Honoraria);
Jeffrey Smith, PhD, MD, FAAD
Biogen – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding);